The therapeutic challenges in the older Parkinson's disease patient

被引:5
|
作者
Playfer, JR [1 ]
机构
[1] Royal Liverpool Univ Hosp, Liverpool L7 8XP, Merseyside, England
关键词
decision theory; Parkinson's disease; rehabilitation;
D O I
10.1046/j.1468-1331.9.s3.7.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The information explosion in Parkinson's disease challenges the individual clinician to apply available knowledge to the management of individual patients. The application of current algorithms and guidelines is not straightforward in the older patient. Decision analysis reveals that clinical decisions may be simple, complex or chaotic. The more factors that have to be taken into account in making a decision, the more that decision moves from being evidence-based to intuitive. Decisions are made within conceptual frameworks. The dominant models in Parkinson's disease are biomedical or rehabilitation-based. Although the rehabilitation model lacks a sound evidence base, it is the principles of rehabilitation that dominate the management of the older patient. Analysis of the decisions made in a Parkinson's disease clinic demonstrates that the doctor's role is complex and many decisions taken are not evidence-based. Parkinson's disease is not a simple movement disorder but a neuro-psychiatric complex. The incurable nature and chronicity of the disease dictate the need for multi-disciplinary working. Quality of life studies reveal wide variations in the expectations and needs of patients. Studies of the impact and costs of the disease put the cost of drugs into perspective. Studies in Parkinson's disease can involve very different populations. A cohort of elderly patients shows significant differences from the populations who are selected to participate in multi-centre trials. There is an increasing challenge for geriatricians to ensure that pragmatic trials are undertaken. Psychiatric problems-dementia, depression, and hallucinations - are common in the elderly and best management of these problems is unclear. Choices in drug regimes need to take into account the complex interactions between ageing, comorbidity and Parkinson's disease.
引用
收藏
页码:55 / 58
页数:4
相关论文
共 50 条
  • [21] Update in therapeutic strategies for Parkinson's disease
    Kulisevsky, Jaime
    Oliveira, Lais
    Fox, Susan H.
    CURRENT OPINION IN NEUROLOGY, 2018, 31 (04) : 439 - 447
  • [22] Dysphagia in Parkinson's disease: a therapeutic challenge?
    Michou, Emilia
    Hamdy, Shaheen
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (06) : 875 - 878
  • [23] The Therapeutic Potential of Salidroside for Parkinson's Disease
    Li, Li
    Yao, Wenlong
    PLANTA MEDICA, 2023, 89 (04) : 353 - 363
  • [24] Kynurenines in Parkinson's disease: therapeutic perspectives
    Zadori, Denes
    Klivenyi, Peter
    Toldi, Jozsef
    Fueloep, Ferenc
    Vecsei, Laszlo
    JOURNAL OF NEURAL TRANSMISSION, 2012, 119 (02) : 275 - 283
  • [25] Nanodelivery of therapeutic agents in Parkinson's disease
    Vicente Lafuente, Jose
    Requejo, Catalina
    Ugedo, Luisa
    NANONEUROPROTECTION AND NANONEUROTOXICOLOGY, 2019, 245 : 263 - 279
  • [26] α-Synuclein: A therapeutic target for Parkinson's disease?
    Maguire-Zeiss, Kathleen A.
    PHARMACOLOGICAL RESEARCH, 2008, 58 (5-6) : 271 - 280
  • [27] Mitochondria: A Therapeutic Target for Parkinson's Disease?
    Luo, Yu
    Hoffer, Alan
    Hoffer, Barry
    Qi, Xin
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (09) : 20704 - 20730
  • [28] Kynurenines in Parkinson’s disease: therapeutic perspectives
    Dénes Zádori
    Péter Klivényi
    József Toldi
    Ferenc Fülöp
    László Vécsei
    Journal of Neural Transmission, 2012, 119 : 275 - 283
  • [29] The Epigenome as a therapeutic target for Parkinson’s disease
    Shane V.Hegarty
    Aideen M.Sullivan
    Gerard W.O’Keeffe
    Neural Regeneration Research, 2016, (11) : 1735 - 1738
  • [30] PPAR: a therapeutic target in Parkinson's disease
    Chaturvedi, Rajnish K.
    Beal, M. Flint
    JOURNAL OF NEUROCHEMISTRY, 2008, 106 (02) : 506 - 518